IOVA (Iovance Biotherapeutics) Moat Score: 4/10 (As of Jun. 27, 2026)


IOVA Iovance Biotherapeutics Inc IOVA
44 GF Score
Price $4.23
GF Value $18.84
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Moat Score?

Iovance Biotherapeutics IOVA +1.07% 44 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.84 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, Iovance Biotherapeutics ranks better than 88.82% on this metric.

Iovance Biotherapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Iovance Biotherapeutics has Narrow Moat: Iovance Biotherapeutics Inc has a discernible but modest moat due to its valuable intellectual property and patents in the biotech sector. However, it faces significant competition and lacks strong pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Iovance Biotherapeutics might have Narrow Moat - Discernible but modest moat.

Iovance Biotherapeutics  (NAS:IOVA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Iovance Biotherapeutics Moat Score Related Terms

IOVA vs HRMY, NRIX, ZYME: Moat Score Comparison

For the Biotechnology subindustry, Iovance Biotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Moat Score falls into.


IOVA
44GF Score
Iovance Biotherapeutics Inc IOVA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Iovance Biotherapeutics (IOVA) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Iovance Biotherapeutics ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Iovance Biotherapeutics' Moat Score too high?
Iovance Biotherapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Iovance Biotherapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Moat Score compare to HRMY and NRIX?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #157 out of 1404 companies for Moat Score. This places Iovance Biotherapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Iovance Biotherapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.84, compared to a current price of $4.23 — trading 77.5% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of $4.23 is trading 77.5% below its estimated GF Value™ of $18.84. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for IOVA:

  • Moat Score: 4
  • GF Value™: $18.84 vs. price of $4.23 (77.5% below fair value)
  • GF Score™: 44/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1404)

No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for IOVA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.23
Price
$18.84
GF Value